STAT3-activating cytokines: A therapeutic opportunity for inflammatory bowel disease?

Journal of Interferon and Cytokine Research

Volumn 35, Issue 5, 2015, Pages 340-350

  Nguyen, Paul M ^a,b   Putoczki, Tracy L ^a,b   Ernst, Matthias ^a,b,c  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 11; INTERLEUKIN 22; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 22; RECOMBINANT INTERLEUKIN 6; STAT3 PROTEIN; UNCLASSIFIED DRUG; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR PROMOTION; ANIMAL; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM;

ANIMALS; CYTOKINES; HOMEOSTASIS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTERLEUKIN-11; INTERLEUKIN-6; INTERLEUKINS; INTESTINAL MUCOSA; STAT3 TRANSCRIPTION FACTOR;

EID: 84928949548     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0225     Document Type: Article

References (121)

1. Alonzi T, Newton IP, Bryce PJ, Di Carlo E, Lattanzio G, Tri-podi M, Musiani P, Poli V. 2004. Induced somatic inactiva-tion of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine 26(2):45-56.
2. Anderson CA, Massey DCO, Barrett JC, Prescott NJ, Tremel-ling M, Fisher SA, Gwilliam R, Jacob J, Nimmo ER, Drummond H, Lees CW, Onnie CM, Hanson C, Blaszczyk K, Ravindrarajah R, Hunt S, Varma D, Hammond N, Lewis G, Attlesey H, Watkins N, Ouwehand W, Strachan D, McArdle W, Lewis CM, Lobo A, Sanderson J, Jewell DP, Deloukas P, Mansfield JC, Mathew CG, Satsangi J, Parkes M. 2009. Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 136(2):523-529.e3.
3. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y. 2005. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129(3):969-984.
4. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nat Med 6(5):583-588.
5. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, McAllister F, Edeal J, Gaus K, Husain S, Kreindler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura Y, Kolls JK. 2008. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14(3):275-281.
6. Backert I, Koralov SB, Wirtz S, Kitowski V, Billmeier U, Martini E, Hofmann K, Hildner K, Wittkopf N, Brecht K, Waldner M, Rajewsky K, Neurath MF, Becker C, Neufert C. 2014. STAT3 activation in Th17 and Th22 cells controls IL-22-mediated epithelial host defense during infectious colitis. J Immunol 193(7):3779-3791.
7. Bao Y, Guo Y, Li Z, Fang W, Yang Y, Li X, Li Z, Xiong B, Chen Z, Wang J, Kang K, Gou D, Yang W. 2014. MicroRNA profiling in Muc2 knockout mice of colitis-associated cancer model reveals epigenetic alterations during chronic colitis malignant transformation. PLoS One 9(6):e99132.
8. Barrett J, Lee J, Lees C, Prescott N, Anderson C, Phillips A, Wesley E, Parnell K, Zhang H, Drummond H, Nimmo E, Massey D, Blaszczyk K, Elliott T, Cotterill L, Dallal H, Lobo A, Mowat C, Sanderson J, Jewell D, Newman W, Edwards C, Ahmad T, Mansfield J, Satsangi J, Parkes M, Mathew C, Donnelly P, Peltonen L, Blackwell J, Bramon E, Brown M, Casas J, Corvin A, Craddock N, Deloukas P, Duncanson A, Jankowski J, Markus H, McCarthy M, Palmer C, Plomin R, Rautanen A, Sawcer S, Samani N, Trembath R, Viswanathan A, Wood N, Spencer C, Bellenguez C, Davison D, Freeman C, Strange A, Langford C, Hunt S, Edkins S, Gwilliam R, Blackburn H, Bumpstead S, Dronov S, Gillman M, Gray E, Hammond N, Jayakumar A, McCann O, Liddle J, Perez M, Potter S, Ravindrarajah R, Ricketts M, Waller M, Weston P, Widaa S, Whittaker P, Attwood A, Stephens J, Sambrook J, Ouwehand W, McArdle W, Ring S, Strachan D. 2009. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 41(12):1330-1334.
9. Baumgart DC, Sandborn WJ. 2012. Crohn's disease. Lancet 380(9853):1590-1605.
10. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Niko-laev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF. 2004. TGF-b suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21(4):491-501.
11. Behnsen J, Jellbauer S, Wong Christina P, Edwards Robert A, George Michael D, Ouyang W, Raffatellu M. 2014. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. Immunity 40(2):262-273.
12. Berg DJ, Davidson N, Kühn R, Müller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D. 1996. En-terocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4( +) TH1-like responses. J Clin Invest 98(4):1010-1020.
13. Bergstrom KSB, Kissoon-Singh V, Gibson DL, Ma C, Montero M, Sham HP, Ryz N, Huang T, Velcich A, Finlay BB, Chadee K, Vallance BA. 2010. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog 6(5): e1000902.
14. Bishop JL, Roberts ME, Beer JL, Huang M, Chehal MK, Fan X, Fouser LA, Ma HL, Bacani JT, Harder KW. 2014. Lyn activity protects mice from DSS colitis and regulates the production of IL-22 from innate lymphoid cells. Mucosal Immunol 7(2):405-416.
15. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR. 2009. gp130-Mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15(2):91-102.
16. Bozza M, Bliss JL, Dorner AJ, Trepicchio WL. 2001. Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4 + T Cells. J Interferon Cytokine Res 21(1):21-30.
17. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte J-M, Diepolder H, Marquardt A, Jagla W, Popp A, Leclair S, Herrmann K, Seiderer J, Ochsenkühn T, Göke B, Auern-hammer CJ, Dambacher J. 2006. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 290(4):G827-G838.
18. Burisch J, Jess T, Martinato M, Lakatos PL. 2013. The burden of inflammatory bowel disease in Europe. J Crohn's Colitis 7(4):322-337.
19. Campbell CL, Guardiani R, Ollari C, Nelson BE, Quesenberry PJ, Savarese TM. 2001. Interleukin-11 receptor expression in primary ovarian carcinomas. Gynecol Oncol 80(2):121-127.
20. Cantor MJ, Nickerson P, Bernstein CN. 2005. The role of cy-tokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol 100(5):1134-1142.
21. Chi H, Zheng X, Wu Z, Dai S, Wan Z, Zou Y. 2014. Association of the interleukin-22 genetic polymorphisms with ulcerative colitis. Diagn Pathol 9(1):183.
22. Cork BA, Tuckerman EM, Li TC, Laird SM. 2002. Expression of interleukin (IL)-11 receptor by the human endometrium in vivo and effects of IL-11, IL-6 and LIF on the production of MMP and cytokines by human endometrial cells in vitro. Mol Hum Reprod 8(9):841-848.
23. Corvaisier M, Delneste Y, Jeanvoine H, Preisser L, Blanchard S, Garo E, Hoppe E, Barré B, Audran M, Bouvard B, Saint-André J-P, Jeannin P. 2012. IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol 10(9):e1001395.
24. Dann SM, Spehlmann ME, Hammond DC, Iimura M, Hase K, Choi LJ, Hanson E, Eckmann L. 2008. IL-6-dependent mu-cosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J Immunol (Baltimore, Md.: 1950) 180(10):6816-6826.
25. Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kühn R, Müller W, Berg DJ, Rennick DM. 1996. T helper cell 1-type CD4 + T cells, but not B cells, mediate colitis in in-terleukin 10-deficient mice. J Exp Med 184(1):241-251.
26. Du X, Williams DA. 1997. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89(11):3897-3908.
27. Dumoutier L, de Meester C, Tavernier J, Renauld J-C. 2009. New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. J Biol Chem 284(39):26377-26384.
28. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld J-C. 2001a. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 167(7):3545-3549.
29. Dumoutier L, Lejeune D, Colau D, Renauld J-C. 2001b. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 166(12):7090-7095.
30. Dumoutier L, Van Roost E, Colau D, Renauld J-C. 2000. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA 97(18): 10144-10149.
31. Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, Takahashi H, Sun H-W, Kanno Y, Powrie F, O'Shea JJ. 2010. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32(5):605-615.
32. Eken A, Singh AK, Treuting PM, Oukka M. 2014. IL-23R + innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol 7(1):143-154.
33. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, Matthews VB, Armes J, Bhathal PS, Hughes NR, Marcusson EG, Karras JG, Na S, Sedgwick JD, Hertzog PJ, Jenkins BJ. 2008. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 118(5):1727-1738.
34. Ernst M, Thiem S, Nguyen PM, Eissmann M, Putoczki TL. 2014. Epithelial gp130/Stat3 functions: an intestinal signaling node in health and disease. Semin Immunol 26(1):29-37.
35. Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, Duan H, Karunasinghe N. 2010. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res 690(1-2):108-115.
36. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359-E386.
37. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellin-ghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PCF, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, Mathew CG, Schreiber S. 2008. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (11):1319.
38. Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel J-F, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot J-P, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PCF, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. 2010. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42(12):1118-1125.
39. Gibson DL, Montero M, Ropeleski MJ, Bergstrom KSB, Ma C, Ghosh S, Merkens H, Huang J, Månsson LE, Sham HP, McNagny KM, Vallance BA. 2010. Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling. Gastroenterology 139(4):1277-1288.
40. Gibson RJ, Keefe DMK, Thompson FM, Clarke JM, et al. 2002. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47(12):2751-2757.
41. Glocker E-O, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora K-W, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. 2009. Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor. N Engl J Med 361(21):2033-2045.
42. Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Val-labhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. 2009. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2):103-113.
43. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu G-Y, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. 2012. Adenoma-linked barrier defects and micro-bial products drive IL-23/IL-17-mediated tumour growth. Nature 491(7423):254-258.
44. Guo X, Qiu J, Tu T, Yang X, Deng L, Anders Robert A, Zhou L, Fu Y-X. 2014. Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. Immunity 40(1):25-39.
45. Helander HF, Fändriks L. 2014. Surface area of the digestive tract-revisited. Scand J Gastroenterol 49(6):681-689.
46. Herrlinger KR, Witthoeft T, Raedler A, Bokemeyer B, Krum-menerl T, Schulzke J-D, Boerner N, Kueppers B, Emmrich J, Mescheder A, Schwertschlag U, Shapiro M, Stange EF. 2006. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 101(4):793-797.
47. Hosokawa T, Kusugami K, Ina K, Ando T, Shinoda M, Imada A, Ohsuga M, Sakai T, Matsuura T, Ito K, Kaneshiro K. 1999. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. Journal of Gastroenterol Hepatol 14(10):987-996.
48. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W, Murphy AJ, Valenzuela DM, Yancopoulos GD, Booth CJ, Cho JH, Ouyang W, Abraham C, Flavell RA. 2012. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491(7423):259-263.
49. Johansson MEV, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. 2008. The inner of the two Muc2 mucin-de-pendent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA 105(39):15064-15069.
50. Jones BC, Logsdon NJ, Walter MR. 2008. Structure of IL-22 bound to its high-affinity IL-22R1 chain. Structure 16(9): 1333-1344.
51. Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, Harrison O, Powrie F. 2013. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 210(5):917-931.
52. Klein W, Tromm A, Griga T, Fricke H, Folwaczny C, Hocke M, Eitner K, Marx M, Duerig N, Epplen JT. 2002. A polymorphism in the IL11 gene is associated with ulcerative colitis. Genes Immun 3(8):494-496.
53. Klein W, Tromm A, Griga T, Fricke H, Folwaczny C, Hocke M, Eitner K, Marx M, Epplen JT. 2001. The polymorphism at position-174 of the IL-6 gene is not associated with inflammatory bowel disease. EurJ Gastroenterol Hepatol 13(1):45-47.
54. Knappe A, Hör S, Wittmann S, Fickenscher H. 2000. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol 74(8):3881-3887.
55. Koss K, Satsangi J, Welsh K, Jewell D. 2000. Is interleukin-6 important in inflammatory bowel disease? Genes Immun 1:207-212.
56. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, Pestka S. 2001. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol 166(12): 7096.
57. Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S. 1997. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 16(19):5894-5903.
58. Kucharzik T, Stoll R, Lügering N, Domschke W. 1995. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 100(3):452-456.
59. Kuhn KA, Manieri NA, Liu T-C, Stappenbeck TS. 2014. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One 9(12):e114195.
60. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75(2):263-274.
61. Lai P-C, Cook HT, Smith J, Keith JC, Pusey CD, Tam FWK. 2001. Interleukin-11 attenuates nephrotoxic nephritis in wistar kyoto rats. J Am Soc Nephrol 12(11):2310-2320.
62. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld J-C. 2002. Interleukin-22 (IL-22) Activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. J Biol Chem 277(37): 33676-33682.
63. Leung JM, Davenport M, Wolff MJ, Wiens KE, Abidi WM, Poles MA, Cho I, Ullman T, Mayer L, Loke P. 2014. IL-22-producing CD4 + cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 7(1):124-133.
64. Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ, van der Woude CJ. 2010. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59(2):227-235.
65. Li Y-Y, Hsieh L-L, Tang R-P, Liao S-K, Yeh K-Y. 2009. Macrophage-derived interleukin-6 up-regulates MUC1, but down-regulates MUC2 expression in the human colon cancer HT-29 cell line. Cell Immunol 256(1-2):19-26.
66. Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A, Eriksen KW, Woetmann A, Ødum N. 2003. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 278(19):16777-16781.
67. Lu P, Burger-van Paassen N, van der Sluis M, Witte-Bouma J, Kerckaert J-P, van Goudoever JB, Van Seuningen I, Renes IB. 2011. Colonic gene expression patterns of mucin muc2 knockout mice reveal various phases in colitis development1. Inflamm Bowel Dis 17(10):2047-2057.
68. Mabbott NA, Donaldson DS, Ohno H, Williams IR, Mahajan A. 2013. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol 6(4): 666-677.
69. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. 2006. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55(2):205-211.
70. Melgar S, Yeung MMW, Bas A, Forsberg G, Suhr O, OBerg A, Hammarstr S, Danielsson A, Hammarstr ML. 2003. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol 134(1):127-137.
71. Mielke LA, Jones SA, Raverdeau M, Higgs R, Stefanska A, Groom JR, Misiak A, Dungan LS, Sutton CE, Streubel G, Bracken AP, Mills KHG. 2013. Retinoic acid expression associates with enhanced IL-22 production by gd T cells and innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med 210(6):1117-1124.
72. Mitsuyama K, Matsumoto S, Rose-John S, Suzuki A, Hara T, Tomiyasu N, Handa K, Tsuruta O, Funabashi H, Scheller J, Toyonaga A, Sata M. 2006. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 55(9):1263-1269.
73. Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, MacDonald TT, Pallone F, Monteleone G. 2011. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 141(1):237-248.e1.
74. Mudter J, Neurath MF. 2007. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 13(8):1016-1023.
75. Mudter J, Weigmann B, Bartsch B, Kiesslich R, Strand D, Galle PR, Lehr HA, Schmidt J, Neurath MF. 2005. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gas-troenterol 100(1):64-72.
76. Naito Y, Takagi T, Uchiyama K, Kuroda M, Kokura S, Ichi-kawa H, Yanagisawa R, Inoue K, Takano H, Satoh M, Yoshida N, Okanoue T, Yoshikawa T. 2004. Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. Int J Mol Med 14(2):191-196.
77. Orazi A. 1996. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 75(1):33.
78. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. 2012. Ulcerative colitis. Lancet 380(9853):1606-1619.
79. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. 2011. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Ann Rev Immunol 29(1):71-109.
80. Palm Noah W, de Zoete Marcel R, Cullen Thomas W, Barry Natasha A, Stefanowski J, Hao L, Degnan Patrick H, Hu J, Peter I, Zhang W, Ruggiero E, Cho Judy H, Goodman Andrew L, Flavell Richard A. 2014. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 158(5):1000-1010.
81. Peterson RL, Wang L, Albert L, Marchese E, Erickson J, Wong A, Mounts WM, Hayes L, Bouchard P, Keith J, Dorner AJ. 2002. Pharmacogenomic analysis of rhIL-11 treatment in the HLA-B27 rat model of inflammatory bowel disease. Phar-macogenomics J 2(6):383-399.
82. Pham Tu Anh N, Clare S, Goulding D, Arasteh Julia M, Stares Mark D, Browne Hilary P, Keane Jacqueline A, Page Andrew J, Kumasaka N, Kane L, Mottram L, Harcourt K, Hale C, Arends Mark J, Gaffney Daniel J, Dougan G, Lawley Trevor D. 2014. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. Cell Host Microbe 16(4):504-516.
83. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, Lehr H-A, Hirth S, Weigmann B, Wirtz S, Ouyang W, Neurath MF, Becker C. 2009. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 206(7):1465-1472.
84. Potten CS. 1995. Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer 62(3): 356-361.
85. Putoczki T, Ernst M. 2010. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 88(6):1109-1117.
86. Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards KM, Boglev Y, Luwor RB, Jarnicki A, Horst D, Boussioutas A, Heath JK, Sieber OM, Pleines I, Kile BT, Nash A, Greten FR, McKenzie BS, Ernst M. 2013. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24(2):257-271.
87. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto J-M, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Si-cheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59-65.
88. Qiu BS, Pfeiffer CJ, Keith JC. 1996. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Digest Dis Sci 41(8):1625-1630.
89. Qiu J, Guo X, Chen Z-ming E, He L, Sonnenberg Gregory F, Artis D, Fu Y-X, Zhou L. 2013. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through Aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 39(2):386-399.
90. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, Granucci F, Kraehenbuhl J-P, Ricciardi-Castagnoli P. 2001. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2(4):361-367.
91. Rigby RJ, Simmons JG, Greenhalgh CJ, Alexander WS, Lund PK. 2007. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 26(33): 4833-4841.
92. Ropeleski MJ, Tang J, Walsh-Reitz MM, Musch MW, Chang EB. 2003. Interleukin-11-induced heat shock protein 25 confers intestinal epithelial-specific cytoprotection from ox-idant stress. Gastroenterology 124(5):1358-1368.
93. Rose-John S. 2012. IL-6 Trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8(9):1237-1247.
94. Sabat R. 2010. IL-10 family of cytokines. Cytokine Growth Factor Rev 21(5):315-324.
95. Sales K, Grant V, Cook I, Maldonado-Pérez D, Anderson R, Williams A, Jabbour H. 2010. Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-pros-tanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol 176(1):435-445.
96. Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US, The Rhil-11 Crohn's Study G. 2002. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 16(3):399-406.
97. Sato K, Shiota M, Fukuda S, Iwamoto E, Machida H, Inamine T, Kondo S, Yanagihara K, Isomoto H, Mizuta Y, Kohno S, Tsukamoto K. 2009. Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. J Clin Immunol 29(6):815-825.
98. Silverberg MS, Cho JH, Rioux JD, McGovern DPB, Wu J, Annese V, Achkar J-P, Goyette P, Scott R, Xu W, Barmada MM, Klei L, Daly MJ, Abraham C, Bayless TM, Bossa F, Griffiths AM, Ippoliti AF, Lahaie RG, Latiano A, Pare P, Proctor DD, Regueiro MD, Steinhart AH, Targan SR, Schumm LP, Kistner EO, Lee AT, Gregersen PK, Rotter JI, Brant SR, Taylor KD, Roeder K, Duerr RH. 2009. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet 41(2):216-220.
99. Sokol H, Conway KL, Zhang M, Choi M, Morin B, Cao Z, Villablanca EJ, Li C, Wijmenga C, Yun SH, Shi HN, Xavier RJ. 2013. Card9 mediates intestinal epithelial cell restitution, T-Helper 17 responses, and control of bacterial infection in mice. Gastroenterology 145(3):591-601.e3.
100. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Hu-marán LG, Gratadoux J-J, Blugeon S, Bridonneau C, Furet J-P, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut micro-biota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105:16731-16736.
101. Spehlmann ME, Manthey CF, Dann SM, Hanson E, Sandhu SS, Liu LY, Abdelmalak FK, Diamanti MA, Retzlaff K, Scheller J, Rose-John S, Greten FR, Wang JYJ, Eckmann L. 2013. Trp53 deficiency protects against acute intestinal inflammation. J Immunol 191(2):837-847.
102. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, Powrie F, Vivier E. 2013. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 13(2):145-149.
103. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A. 2008. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118(2):534-544.
104. Takagi M, Nakamura T, Sawada T, Kaneko A, Nozaki-Ukai M, Nakahata T, Yokota T, Heike T. 1999. Chimeric cytokine receptor can transduce expansion signals in interleukin 6 receptor a (IL-6Ra)-, IL-11Ra-, and gp130-low to-negative primitive hematopoietic progenitors. Mol Biol Cell 10(11): 3633-3642.
105. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Förster I, Akira S. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10(1):39-49.
106. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, Malki S, Alderman BM, Grail D, Hollande F, Heath JK, Ernst M. 2002. Reciprocal regulation of gastrointestinal ho-meostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8(10):1089-1097.
107. Torrence AE, Brabb T, Viney JL, Bielefeldt-Ohmann H, Treuting P, Seamons A, Drivdahl R, Zeng W, Maggio-Price L. 2008. Serum biomarkers in a mouse model of bacterial-induced inflammatory bowel disease. Inflamm Bowel Dis 14(4): 480-490.
108. Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld J-C, Dumoutier L. 2012. IL-22 is required for imiquimod-in-duced psoriasiform skin inflammation in mice. J Immunol 188(1):462-469.
109. Wang X, Sumida H, Cyster JG. 2014. GPR18 is required for a normal CD8aa intestinal intraepithelial lymphocyte compartment. J Exp Med 211(12):2351-2359.
110. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schäffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schröder JM, Bevins CL, Fellermann K, Stange EF. 2004. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal a-defensin expression. Gut 53(11):1658-1664.
111. Wilson J, Hair C, Knight R, Catto-Smith A, Bell S, Kamm M, Desmond P, McNeil J, Connell W. 2010. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis 16(9):1550-1556.
112. Wolk K, Haugen H, Xu W, Witte E, Waggie K, Anderson M, Baur E, Witte K, Warszawska K, Philipp S, Johnson-Leger C, Volk H-D, Sterry W, Sabat R. 2009. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-g are not. J Mol Med 87(5):523-536.
113. Wolk K, Kunz S, Asadullah K, Sabat R. 2002. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 168(11):5397-5402.
114. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. 2004. IL-22 increases the innate immunity of tissues. Immunity 21(2):241.
115. Yang L, Wang R, Gao Y, Xu X, Fu K, Wang S, Li Y, Peng R. 2014. The Protective role of interleukin-11 against neutron radiation injury in mouse intestines via MEK/ERK and PI3K/Akt dependent pathways. Digest Dis Sci 59(7):1406-1414.
116. Yeste A, Mascanfroni ID, Nadeau M, Burns EJ, Tukpah A-M, Santiago A, Wu C, Patel B, Kumar D, Quintana FJ. 2014. IL-21 induces IL-22 production in CD4+ T cells. Nat Commun 5:3753.
117. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. 2007. Interleukin-22 but not inter-leukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27(4):647-659.
118. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. 2008. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29(6):947-957.
119. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ, Ouyang W. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14(3): 282-289.
120. Zindl CL, Lai J-F, Lee YK, Maynard CL, Harbour SN, Ouyang W, Chaplin DD, Weaver CT. 2013. IL-22-producing neu-trophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc Natl Acad Sci USA 110(31):12768-12773.
121. Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, Arap W. 2004. Combinatorial screenings in patients: the interleukin-11 receptor a as a candidate target in the progression of human prostate cancer. Cancer Res 64(2):435-439.